We are a small clinical-stage drug development company with a focus on developing therapeutics for Duchenne muscular dystrophy. We run under a venture philanthropy model, through collaborations and partnerships with non-profit foundations and government agencies in both the US and the EU. As such, we keep the focus on stake holders rather than stock holders.
Our lead compound, vamorolone is a steroidal-type anti-inflammatory that has multiple additional properties chemically tuned for DMD. These value added features include epleronone-like properties to improve heart function, and membrane stabilization properties to counteract dystrophin deficiency. Phase 1 clinical trial data in adult volunteers has shown that vamorolone no longer has many of the side effects seen with traditional corticosteroids, such as prednisone and deflazacort.
ReveraGen’s confict of interest policy can be found here.